Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. My name is Rochelle, and I will be your ...

Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of food-associated allergic and inflammatory diseases.

Immunosuppressive factors prevent killer T cells from defeating brain tumors that arise from primary breast cancer.

A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of ...

A decade ago, a clinical trial in the U.K. famously showed that children who were exposed to peanuts in the early months of ...

CCR8 is highly expressed on immunosuppressive regulatory T cells (Tregs) in various solid tumors, making it a potential target to enhance antitumor immunity and the efficacy of cancer therapies, ...

In a new study published in Cell Reports, researchers at the University of Freiburg reveal how a disordered protein segment ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online ...

From my colleague Jason Mast: The first ever patient has been treated with prime editing, a powerful technology for making ...

Total Operating Expenses: Total operating expenses were $42.9 million for the first quarter of 2025, including research and ...

Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...